Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Goldman Sachs and T. Rowe to add private equity and credit to 401(k) plans
Goldman Sachs and T. Rowe to add private equity and credit to 401(k) plans Goldman Sachs and T. Rowe Price will launch new alternative investment options for US retirement accounts by the end of 2025, tapping into a $9tn pool of 401(k) assets following a regulatory...
CVC eyes KKR’s 63% stake in India’s Avendus amid stalled Mizuho deal
CVC eyes KKR’s 63% stake in India’s Avendus amid stalled Mizuho deal CVC Capital Partners has entered discussions to acquire KKR’s majority stake in Mumbai-based Avendus Capital, as Japanese lender Mizuho Financial Group’s bid stalls, according to sources familiar...
Blackstone retains 74% control as Legence lists at $3.2bn valuation
Blackstone retains 74% control as Legence lists at $3.2bn valuation Blackstone-backed Legence made its Nasdaq debut on Friday, closing its first day of trading at a $3.2bn market valuation after raising $728m in its IPO, according to a report by Reuters. Shares in the...